|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/23/22 Bone Biologics Corp. S-1 58:7.9M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: S-1 Registration Statement (General Form) HTML 2.42M
2: EX-1.1 Underwriting Agreement or Conflict Minerals Report HTML 365K
3: EX-4.2 Instrument Defining the Rights of Security Holders HTML 533K
4: EX-23.1 Consent of Expert or Counsel HTML 16K
5: EX-FILING FEES Filing Fees HTML 25K
11: R1 Cover HTML 51K
12: R2 Consolidated Balance Sheets HTML 78K
13: R3 Consolidated Balance Sheets (Parenthetical) HTML 35K
14: R4 Consolidated Statements of Operations HTML 87K
15: R5 Consolidated Statement of Stockholders' Equity HTML 71K
(Deficit)
16: R6 Consolidated Statement of Stockholders' Equity HTML 18K
(Deficit) (Parenthetical)
17: R7 Consolidated Statements of Cash Flows HTML 77K
18: R8 The Company HTML 50K
19: R9 Summary of Significant Accounting Policies HTML 84K
20: R10 Notes Payable - Related Party HTML 55K
21: R11 Stockholders? Deficit HTML 86K
22: R12 Stock-based Compensation HTML 160K
23: R13 Income Taxes HTML 55K
24: R14 Related Party Transactions HTML 21K
25: R15 Deferred Compensation HTML 22K
26: R16 Commitments and Contingencies HTML 73K
27: R17 Subsequent Events HTML 30K
28: R18 Summary of Significant Accounting Policies HTML 113K
(Policies)
29: R19 Summary of Significant Accounting Policies HTML 34K
(Tables)
30: R20 Notes Payable - Related Party (Tables) HTML 38K
31: R21 Stockholders? Deficit (Tables) HTML 65K
32: R22 Stock-based Compensation (Tables) HTML 143K
33: R23 Income Taxes (Tables) HTML 52K
34: R24 The Company (Details Narrative) HTML 83K
35: R25 Schedule of Antidilutive Securities Excluded from HTML 28K
Computation of Earnings Per Share (Details)
36: R26 Summary of Significant Accounting Policies HTML 24K
(Details Narrative)
37: R27 Schedule of Notes Payable (Details) HTML 41K
38: R28 Notes Payable - Related Party (Details Narrative) HTML 69K
39: R29 Schedule of Warrant Activity (Details) HTML 43K
40: R30 Schedule of Outstanding Vested and Unexercised HTML 36K
Common Stock Warrants (Details)
41: R31 Stockholders? Deficit (Details Narrative) HTML 70K
42: R32 Schedule of Stock Option Activity (Details) HTML 51K
43: R33 Schedule of Outstanding Stock Options (Details) HTML 67K
44: R34 Schedule of Assumptions Using Black-Scholes Option HTML 34K
Pricing Model (Details)
45: R35 Stock-based Compensation (Details Narrative) HTML 34K
46: R36 Schedule of Provision for Income Taxes (Details) HTML 40K
47: R37 Schedule of Deferred Tax Assets and Liabilities HTML 33K
(Details)
48: R38 Schedule of Income Tax Effective Tax Rate HTML 34K
(Details)
49: R39 Income Taxes (Details Narrative) HTML 25K
50: R40 Deferred Compensation (Details Narrative) HTML 32K
51: R41 Commitments and Contingencies (Details Narrative) HTML 64K
52: R42 Schedule of Stock Options Non-vested (Details) HTML 46K
53: R43 Subsequent Events (Details Narrative) HTML 41K
56: XML IDEA XML File -- Filing Summary XML 98K
54: XML XBRL Instance -- forms-1_htm XML 1.38M
55: EXCEL IDEA Workbook of Financial Reports XLSX 106K
7: EX-101.CAL XBRL Calculations -- bblg-20220630_cal XML 95K
8: EX-101.DEF XBRL Definitions -- bblg-20220630_def XML 446K
9: EX-101.LAB XBRL Labels -- bblg-20220630_lab XML 886K
10: EX-101.PRE XBRL Presentations -- bblg-20220630_pre XML 634K
6: EX-101.SCH XBRL Schema -- bblg-20220630 XSD 135K
57: JSON XBRL Instance as JSON Data -- MetaLinks 280± 405K
58: ZIP XBRL Zipped Folder -- 0001493152-22-026702-xbrl Zip 622K
Exhibit 107
CALCULATION OF REGISTRATION FEE
| Title of Each Class of Securities to be Registered | Proposed
Maximum Aggregate Offering Price(1)(6) |
Amount
of Registration Fee(2) |
||||||
| Units(3) | $ | 5,000,000.00 | $ | 463.50 | ||||
| Shares of Common Stock, par value $0.001 per share, included in the Units | ||||||||
| Series A Warrants included in the Units(7) | ||||||||
| Series B Warrants included in the Units(8) | ||||||||
| Series C Warrants included in the Units(9) | ||||||||
| Shares of Common Stock underlying the Series A Warrants included in the Units | $ | 6,000,000.00 | $ | 556.20 | ||||
| Shares of Common Stock underlying the Series B Warrants included in the Units | $ | 8,000,000.00 | $ | 741.60 | ||||
| Shares of Common Stock underlying the Series C Warrants included in the Units | $ | 5,000,000.00 |
$ | 463.50 |
||||
| Warrants to purchase common stock to be issued to the Underwriters(4)(5) | $ | - | $ | - | ||||
| Common stock issuable upon exercise of warrants to purchase common stock to be issued to the Underwriters(4) | $ | 300,000.00 | $ | 27.81 | ||||
| Total: | $ | 24,300,000.00 | $ | 2,252,61 | ||||
| (1) | Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes shares of common stock that the underwriters have the option to purchase to cover over-allotments, if any. |
| (2) | Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price of the securities registered hereunder to be sold by the registrant. |
| (3) | Each Unit consists of: (i) one share of Common Stock; (ii) one Series A Warrant; (iii) one Series B Warrant and (iv) one Series C Warrant, each whole warrant exercisable for one share of common stock. |
| (4) | We have agreed to issue to the underwriters, upon closing of this offering, Warrants to purchase 5% of the number of shares of common stock sold in this offering. Resales of shares of common stock issuable upon exercise of the underwriters’ warrants are being similarly registered on a delayed or continuous basis. We have calculated the proposed maximum aggregate offering price of the common stock underlying the underwriters’ warrants by assuming that such warrants are exercisable at a price per share equal to 120% of the price per share sold in this offering. |
| (5) | No fee required pursuant to Rule 457(g). |
| (6) | Pursuant to Rule 416 under the Securities Act, there is also being registered hereby such indeterminate number of additional shares of common stock of the Registrant as may be issued or issuable because of stock splits, stock dividends, stock distributions, and similar transactions. |
| (7) | Series A Warrants are exercisable at a price per common share of $ _________. |
| (8) | Series B Warrants are exercisable at a price per common share of $ _________. |
| (9) | Series C Warrants are exercisable at a price per common share of $ _________. |
C:
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/20/23 Bone Biologics Corp. 10-K/A 12/31/22 14:425K M2 Compliance LLC/FA 6/13/23 Bone Biologics Corp. S-1/A 6:1M M2 Compliance LLC/FA 6/06/23 Bone Biologics Corp. S-1/A 6:1M M2 Compliance LLC/FA 5/01/23 Bone Biologics Corp. S-1 5:758K M2 Compliance LLC/FA 3/30/23 Bone Biologics Corp. 10-K 12/31/22 58:5.5M M2 Compliance LLC/FA 10/07/22 Bone Biologics Corp. S-1MEF 10/07/22 4:117K M2 Compliance LLC/FA 10/07/22 Bone Biologics Corp. S-1MEF 10/07/22 4:119K M2 Compliance LLC/FA |